Kane Biotech to Release First Quarter 2024 Financial Results on May 23, 2024
Kane Biotech (TSX-V:KNE; OTCQB:KNBIF), a biotechnology firm specializing in microbial biofilm prevention and removal technologies, will disclose its Q1 2024 financial results on May 23, 2024, after market close.
The company’s management will present a corporate update at a Special and Annual General Meeting via videoconference on May 22, 2024, at 5:00pm EST.
Participants can register for the meeting using the provided link.
- Kane Biotech is set to release its Q1 2024 financial results, which can provide fresh insights into the company's financial health and performance.
- The management's corporate update at the AGM may include strategic plans, recent achievements, and future directions, potentially boosting investor confidence.
- Releasing financial results after market close may indicate potential volatility in the stock price.
- Holding the AGM via videoconference could limit investor engagement and stakeholder interaction.
WINNIPEG, Manitoba, May 16, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”), a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms, will release its first quarter 2024 financial results after market close on Thursday, May 23, 2024.
Kane Biotech management will be providing a corporate update at its Special and Annual General Meeting to be held via videoconference at 5:00pm EST on Wednesday, May 22, 2024. Participants can register for this meeting using the following link: Kane AGM
About Kane Biotech
Kane Biotech is a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms. The Company has a portfolio of biotechnologies, intellectual property (67 patents and patents pending, trade secrets and trademarks) and products developed by the Company's own biofilm research expertise and acquired from leading research institutions. StrixNB™, DispersinB®, Aledex™, coactiv+™, coactiv+®, DermaKB™, DermaKB Biofilm™, and revyve™ are trademarks of Kane Biotech Inc. The Company is listed on the TSX Venture Exchange under the symbol "KNE" and on the OTCQB Venture Market under the symbol “KNBIF”.
For more information:
Marc Edwards | Ray Dupuis | ||||
Chief Executive Officer | Chief Financial Officer | ||||
Kane Biotech Inc | Kane Biotech Inc | ||||
medwards@kanebiotech.com | rdupuis@kanebiotech.com |
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Caution Regarding Forward-Looking Information
This press release contains certain statements regarding Kane Biotech Inc. that constitute forward-looking information under applicable securities law. These statements reflect management’s current beliefs and are based on information currently available to management. Certain material factors or assumptions are applied in making forward-looking statements, and actual results may differ materially from those expressed or implied in such statements. These risks and uncertainties include, but are not limited to, risks relating to the Company’s: (a) financial condition, including lack of significant revenues to date and reliance on equity and other financing; (b) business, including its early stage of development, government regulation, market acceptance for its products, rapid technological change and dependence on key personnel; (c) intellectual property including the ability of the Company to protect its intellectual property and dependence on its strategic partners; and (d) capital structure, including its lack of dividends on its common shares, volatility of the market price of its common shares and public company costs. Further information about these and other risks and uncertainties can be found in the disclosure documents filed by the Company with applicable securities regulatory authorities, available at www.sedar.com. The Company cautions that the foregoing list of factors that may affect future results is not exhaustive.`
![](https://ml.globenewswire.com/media/N2M1MjExZmEtMzBmZi00ZWFlLTk1OGUtNTFlMGU0MjZmNjQ3LTExMDIxMTM=/tiny/Kane-Biotech-Inc-.png)
FAQ
When will Kane Biotech release its Q1 2024 financial results?
What is the ticker symbol for Kane Biotech?
When is Kane Biotech's Special and Annual General Meeting for 2024?